284 results on '"Kauh, John"'
Search Results
2. LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial
3. A phase 1b/2 study to evaluate the safety and efficacy of TTI-101 as monotherapy and in combination in advanced hepatocellular carcinoma.
4. Supplementary Table S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
5. Supplementary Figure S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
6. Supplemental Figure 1 from Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors
7. Supplementary Materials and Methods from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
8. Supplementary Table 1 from An Open-Label, Dose–Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma
9. Supplementary Tables 1-2, Supplementary Methods, Supplementary Figure Legend from Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors
10. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors
11. A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors
12. Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer
13. Safety and Efficacy of Doxorubicin Drug-eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma
14. REVERT-IPF STUDY: FROM PRECLINICAL POC TO ACTIVELY ENROLLING CLINICAL TRIAL TARGETING THE SINGULAR NODE IN FIBROSIS WITH TTI-101, AN INHIBITOR OF STAT3
15. Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E4203)
16. Safety and Feasibility of Same-day Discharge of Patients with Unresectable Hepatocellular Carcinoma Treated with Doxorubicin Drug-eluting Bead Transcatheter Chemoembolization
17. Microvessel Density Analysis in Patients with Viral Hepatitis-Related Hepatocellular Carcinoma
18. Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
19. Surufatinib in U.S. patients with soft tissue sarcoma.
20. Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group
21. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study
22. The Effectiveness of Locoregional Therapies versus Supportive Care in Maintaining Survival within the Milan Criteria in Patients with Hepatocellular Carcinoma
23. Comparison of Yttrium-90 Radioembolization and Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma
24. Yttrium-90 Radioembolization for Unresectable Standard-chemorefractory Intrahepatic Cholangiocarcinoma: Survival, Efficacy, and Safety Study
25. Clinically Relevant Biomarkers to Select Patients for Targeted Inhibitor Therapy after Resection of Hepatocellular Carcinoma
26. Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after Resection
27. Chemotherapy in the Treatment of Metastatic Gastric Cancer: Is There a Global Standard?
28. Early Clinical Results from Chemoradiation with 5-Fluorouracil and Oxaliplatin for Locally Advanced Rectal Cancer
29. Treatment Utilization and Surgical Outcome of Ampullary and Duodenal Adenocarcinoma
30. Racial Disparities in Colorectal Cancer
31. Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs).
32. A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations.
33. An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors.
34. Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base
35. The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma
36. Gastric cancer: Standards for the 21st century
37. Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial
38. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
39. Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies§
40. Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
41. Abstract CT115: Efficacy of surufatinib in Western patients with pancreatic neuroendocrine tumors
42. Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs).
43. Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer
44. The Value of New Chemotherapeutic Agents for Metastatic Colorectal Cancer
45. A black-white comparison of the quality of stage-specific colon cancer treatment
46. Changing Management and Outcome of Hepatocellular Carcinoma: Evaluation of 501 Patients Treated at a Single Comprehensive Center
47. State of the art: Gastrointestinal malignancies in the human immunodeficiency virus (HIV) population
48. Colorectal cancer prevention
49. A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer
50. Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.